Deep Dive: Page 7
Industry insights from our journalists
-
Wave of deals expected as private equity eyes orthopaedic practices
The business of replacing hips and knees is a lucrative area for investors as joint replacements are expected to rise and more care migrates to outpatient settings.
Oct. 25, 2019 -
5 insights from a chat with Larry Merlo, CEO of CVS Health
Healthcare Dive talked to Merlo, who rose up the ranks to lead the giant chain over three decades, about CVS' rivals, the path to the Aetna acquisition and potential arenas for disruption.
Rebecca Pifer • Oct. 23, 2019 -
Danielle Ternes/Healthcare Dive
The forgotten ones: Ransomware preys on the resource-poor
When Brookside Medical Center was hit with ransomware, it refused to pay. The practice was forced to shutter.
Samantha Schwartz • Oct. 18, 2019 -
Is the future of diabetes treatment better drugs or better care?
Drug manufacturers are trying to push the boundaries of glucose control, but cost concerns could rein in ambitions.
Jonathan Gardner • Sept. 24, 2019 -
Amyloid's last hope? Prevention studies next big test for Alzheimer's research
The DIAN-TU trial, studying patients genetically predisposed to Alzheimer's, could help decide the fate of what's been the dominant hypothesis of the disease's cause.
Jonathan Gardner • Aug. 29, 2019 -
Pharmacogenetic test makers cheer UnitedHealth coverage. Other payers aren't there yet
"I've been concerned that the hype around pharmacogenetics, at least for depression, has gotten out ahead of the data," James Potash, director of psychiatry at Johns Hopkins University, said.
Graison Dangor • Aug. 28, 2019 -
From wellness to well-being: the evolution of employer health initiatives
What started as on-site yoga classes and smoking cessation programs has evolved into something more holistic and wide-reaching.
Pamela DeLoatch • Aug. 28, 2019 -
Employers say wellness programs are working. Why do employees disagree?
"The paradigm of the past is bringing people to benefits," one source told HR Dive, "but I think more of what needs to occur is bringing benefits to the people."
Ryan Golden • Aug. 26, 2019 -
ACA's legal jeopardy: 4 questions
The embattled landmark law is again before jurists, this time a panel of the Fifth Circuit Court of Appeals. Arguments this week offered more insight into what's at stake.
Shannon Muchmore, Samantha Liss and Dana Elfin • July 11, 2019 -
Brian Tucker/Healthcare Dive
Could NEMT's pivot to the commercial sector be a wrong turn?
Employers and commercial plans are increasingly looking to partner with players like Uber and Lyft for non-emergency medical transportation, raising thorny questions about the return on investment in a healthier population.
Rebecca Pifer • July 2, 2019 -
Once 'bodies for hire,' CROs are finding a new role as data specialists
Drugmakers and regulators are paying more attention to what real-world data can prove — driving demand for contract research providers to help keep up.
Jacob Bell • June 28, 2019 -
Hospital price transparency push draws industry ire, but effects likely limited
While few would argue for secrecy for its own sake, policy analysts say there's little evidence patients use the information now available to make decisions that could bend the cost curve.
Shannon Muchmore • June 25, 2019 -
Industry interoperability concerns plague TEFCA draft
ONC's "on-ramp" to nationwide connectivity is being dogged by many of the same issues as its interoperability regulations, including implementation, standardization and privacy.
Rebecca Pifer • June 20, 2019 -
Getty / Edited by BioPharma Dive
The gene therapy era has arrived. So have the challenges.
The chief medical officer for Harvard Pilgrim Health Care said Medicaid pricing law needs to change to enable flexibility for payers as they navigate a world with $2.1 million treatments.
Andrew Dunn • June 10, 2019 -
Danielle Ternes/Healthcare Dive
On the path to patients, NASH drugs may hit a payer roadblock
Wall Street estimates and clinical data suggest the earliest NASH drugs could come with limited efficacy but high price tags. Healthcare providers fear that won't sit well with payers.
Jacob Bell • May 15, 2019 -
Hospitals look to venture capital as R&D extension
UPMC Enterprises President Tal Heppenstall told Healthcare Dive the University of Pittsburgh Medical Center venture arm plans on spinning out two companies by the middle of this year.
Tony Abraham • April 3, 2019 -
Scale: blessing or burden for statewide ACOs?
Caravan Health launched its second statewide ACO last week. Some experts worry the scale of the models means Caravan is biting off more than it can chew.
Rebecca Pifer • March 27, 2019 -
Private equity sees ripe opportunity in healthcare this year
Attractive targets include orthopaedics, gastroenterology and urology practices and mental health and addiction services.
Samantha Liss • March 25, 2019 -
As 5G looms, most hospitals watch from the sidelines
Chicago's Rush is an early mover with the tech, but many other big systems are taking a wait-and-see approach.
Rebecca Pifer • March 21, 2019 -
Mixing medicine and money: Why the rise of health system VCs is raising ethical concerns
More dollars than ever are flowing from VCs affiliated with nonprofit health systems, spurring questions around conflicts of interest.
Andrew Dunn • March 4, 2019 -
4 main takeaways from HIMSS19
Digest the biggest health IT conference of the year with this roundup of what grabbed the attention of more than 43,000 health execs, policymakers and academics.
David Lim and Rebecca Pifer • Feb. 15, 2019 -
HIMSS19: Private sector catch-up, patient matching and standard APIs dominate first full day
Support for the HHS rules (but some concern over implementation) was the focus at the start of health IT's biggest week.
Rebecca Pifer • Feb. 13, 2019 -
Hospital lobby ramps up 'Medicare for all' opposition
As more Democratic presidential hopefuls embrace the idea, health systems and providers have picked up lobbying efforts arguing it would shutter hospitals.
Tony Abraham • Feb. 8, 2019 -
With CMS depression device on the line, analysts eye multibillion potential market
The government insurer may cover a clinical trial of LivaNova's vagus nerve stimulation in some cases as a last resort for severe depression. At the same time, some patients are turning to less invasive tech-driven therapies.
Maria Rachal • Feb. 7, 2019 -
Clinical lab lobbying spikes as PAMA cuts kick into effect
Paralleling CMS payment cuts that took effect at the start of last year, lobbying by Quest Diagnostics, LabCorp and the American Clinical Laboratory Association jumped to $4.4 million, up from $2.5 million in 2017.
David Lim • Feb. 4, 2019
Previous
